Skip to main
QNCX

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics is facing some setbacks with their Phase 3 asset, eDSP, missing in the Phase 3 NEAT trial for treating a pediatric neurodegenerative disease, A-T. This has caused a downgraded rating to Market Perform from Market Outperform. The company faces risks such as clinical and regulatory uncertainty, as well as potential market share and valuation erosion.

Bears say

Quince Therapeutics is facing several fundamental challenges, including the failure of its lead candidate eDSP in the Phase 3 NEAT trial for A-T, discontinued clinical development of eDSP, a lack of revenue projections, and an uncertain pipeline with a single asset and potential regulatory complexities. Additionally, the company may need to raise additional capital and faces the risks associated with commercializing a drug for a rare disease market. These factors contribute to a negative outlook for Quince's stock.

QNCX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 2 analysts, QNCX has a Buy consensus rating as of Jun 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.